Angela Nebbioso

List of Publications by Year
in descending order

116 papers	6,475 citations	61984 43 h-index	71685 76 g-index
118 all docs	118 docs citations	118 times ranked	10250 citing authors

#	Article	IF	Citations
1	Relevance of AIF/CypA Lethal Pathway in SH-SY5Y Cells Treated with Staurosporine. International Journal of Molecular Sciences, 2022, 23, 265.	4.1	5
2	SIRT1 pharmacological activation rescues vascular dysfunction and prevents thrombosis in MTHFR deficiency. Cellular and Molecular Life Sciences, 2022, 79, .	5.4	14
3	Recent insights intoHistone Acetyltransferase-1: biological function and involvement in pathogenesis. Epigenetics, 2021, 16, 838-850.	2.7	21
4	Different Approaches to Unveil Biomolecule Configurations and Their Mutual Interactions. Analytical Letters, 2021, 54, 40-56.	1.8	1
5	Novel Pyridineâ€Based Hydroxamates and 2â€²â€Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. ChemMedChem, 2021, 16, 989-999.	3.2	8
6	The Role of Necroptosis: Biological Relevance and Its Involvement in Cancer. Cancers, 2021, 13, 684.	3.7	27
7	Gene Transactivation and Transrepression in MYC-Driven Cancers. International Journal of Molecular Sciences, 2021, 22, 3458.	4.1	18
8	Antiviral Activity of Vitis vinifera Leaf Extract against SARS-CoV-2 and HSV-1. Viruses, 2021, 13, 1263.	3.3	53
9	Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer Therapy. Marine Drugs, 2021, 19, 15.	4.6	12
10	KDM4 Involvement in Breast Cancer and Possible Therapeutic Approaches. Frontiers in Oncology, 2021, 11, 750315.	2.8	17
11	DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment. Epigenetics, 2020, 15, 439-453.	2.7	46
12	SIRT1 Activation by Natural Phytochemicals: An Overview. Frontiers in Pharmacology, 2020, 11, 1225.	3.5	146
13	The KDM Inhibitor GSKJ4 Triggers CREB Downregulation via a Protein Kinase A and Proteasome-Dependent Mechanism in Human Acute Myeloid Leukemia Cells. Frontiers in Oncology, 2020, 10, 799.	2.8	15
14	The Pan-Sirtuin Inhibitor MC2494 Regulates Mitochondrial Function in a Leukemia Cell Line. Frontiers in Oncology, 2020, 10, 820.	2.8	8
15	Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation. Cancers, 2020, 12, 447.	3.7	8
16	Trifolium Repens Blocks Proliferation in Chronic Myelogenous Leukemia via the BCR-ABL/STAT5 Pathway. Cells, 2020, 9, 379.	4.1	12
17	Comparative Phytochemical Characterization, Genetic Profile, and Antiproliferative Activity of Polyphenol-Rich Extracts from Pigmented Tubers of Different Solanum tuberosum Varieties. Molecules, 2020, 25, 233.	3.8	29
18	Two novel SIRT1 activators, SCIC2 and SCIC2.1, enhance SIRT1-mediated effects in stress response and senescence. Epigenetics, 2020, 15, 664-683.	2.7	23

#	Article	IF	Citations
19	Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDACâ€MEF2 complexes. EMBO Reports, 2020, 21, e51028.	4.5	1
20	Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. Clinical Epigenetics, 2019, 11, 68.	4.1	30
21	BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition. Cell Death and Disease, 2019, 10, 338.	6.3	31
22	Discovery of the First-in-Class GSK-3Î²/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimerâ€™s Disease. ACS Medicinal Chemistry Letters, 2019, 10, 469-474.	2.8	32
23	Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. Frontiers in Pharmacology, 2019, 10, 38.	3.5	128
24	Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer. International Journal of Molecular Sciences, 2019, 20, 5654.	4.1	16
25	Inhibition of Histone Demethylases LSD1 and UTX Regulates ERÎ± Signaling in Breast Cancer. Cancers, 2019, 11, 2027.	3.7	34
26	Oxidative nucleophilic substitution selectively produces cambinol derivatives with antiproliferative activity on bladder cancer cell lines. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 78-82.	2.2	12
27	Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents. European Journal of Medicinal Chemistry, 2019, 162, 290-320.	5.5	31
28	The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia. Oncogene, 2018, 37, 2559-2572.	5.9	32
29	Designing Dual Transglutaminaseâ€…2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death. ChemMedChem, 2018, 13, 227-230.	3.2	13
30	RIP1â€“HAT1â€“SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer. Clinical Cancer Research, 2018, 24, 2886-2900.	7.0	40
31	Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. Oncotarget, 2018, 9, 25647-25660.	1.8	13
32	Biological interactions of biocompatible and water-dispersed MoS2 nanosheets with bacteria and human cells. Scientific Reports, 2018, 8, 16386.	3.3	66
33	3-Chloro-Nâ€²-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy. Frontiers in Pharmacology, 2018, 9, 1006.	3.5	14
34	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies. European Journal of Medicinal Chemistry, 2018, 157, 127-138.	5.5	39
35	Forskolin Sensitizes Human Acute Myeloid Leukemia Cells to H3K27me2/3 Demethylases GSKJ4 Inhibitor via Protein Kinase A. Frontiers in Pharmacology, 2018, 9, 792.	3.5	13
36	Synthesis and Biological Evaluation of Tripartin, a Putative KDM4 Natural Product Inhibitor, and 1â€Dichloromethylindenâ€1â€ol Analogues. ChemMedChem, 2018, 13, 1949-1956.	3.2	13

#	Article	IF	Citations
37	Cancer epigenetics: Moving forward. PLoS Genetics, 2018, 14, e1007362.	3.5	364
38	Combined HAT/EZH2 modulation leads to cancer-selective cell death. Oncotarget, 2018, 9, 25630-25646.	1.8	5
39	c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. Clinical Cancer Research, 2017, 23, 2542-2555.	7.0	105
40	Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human Deacetylase Sirtuin 2: Structureâ€“Activity Relationship, X-ray Crystal Structure, and Anticancer Activity. Journal of Medicinal Chemistry, 2017, 60, 2344-2360.	6.4	82
41	Time-resolved analysis of DNA-protein interactions in living cells by UV laser pulses. Scientific Reports, 2017, 7, 11725.	3.3	11
42	Identification and characterization of PKF118-310 as a KDM4A inhibitor. Epigenetics, 2017, 12, 198-205.	2.7	36
43	1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells. Journal of Medicinal Chemistry, 2016, 59, 1471-1491.	6.4	60
44	â€œStockpileâ€•of Slight Transcriptomic Changes Determines the Indirect Genotoxicity of Low-Dose BPA in Thyroid Cells. PLoS ONE, 2016, 11, e0151618.	2.5	32
45	HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape. Oncotarget, 2015, 6, 886-901.	1.8	27
46	Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia. Expert Opinion on Therapeutic Targets, 2015, 19, 1187-1202.	3.4	16
47	Anticancer activities of anthocyanin extract from genotyped Solanum tuberosum L. â€œVitelotteâ€• Journal of Functional Foods, 2015, 19, 584-593.	3.4	43
48	ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias. Epigenetics, 2015, 10, 6-18.	2.7	29
49	Antiproliferative, Antibacterial and Antifungal Activity of the Lichen Xanthoria parietina and Its Secondary Metabolite Parietin. International Journal of Molecular Sciences, 2015, 16, 7861-7875.	4.1	77
50	Context-Selective Death of Acute Myeloid Leukemia Cells Triggered by the Novel Hybrid Retinoid-HDAC Inhibitor MC2392. Cancer Research, 2014, 74, 2328-2339.	0.9	33
51	Identification of NuRSERY, a new functional HDAC complex composed by HDAC5, GATA1, EKLF and pERK present in human erythroid cells. International Journal of Biochemistry and Cell Biology, 2014, 50, 112-122.	2.8	23
52	Evaluation of a large library of (thiazol-2-yl)hydrazones and analogues as histone acetyltransferase inhibitors: Enzyme and cellular studies. European Journal of Medicinal Chemistry, 2014, 80, 569-578.	5.5	54
53	1,3,4-Oxadiazole-Containing Histone Deacetylase Inhibitors: Anticancer Activities in Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 6259-6265.	6.4	102
54	Novel Antiproliferative Chimeric Compounds with Marked Histone Deacetylase Inhibitory Activity. ACS Medicinal Chemistry Letters, 2014, 5, 973-978.	2.8	13

#	Article	IF	Citations
55	Natural compounds in epigenetics: A current view. Food and Chemical Toxicology, 2014, 73, 71-83.	3.6	35
56	Analysis of Chromatinâ€“Nuclear Receptor Interactions by Laser-Chromatin Immunoprecipitation. Methods in Molecular Biology, 2014, 1204, 25-34.	0.9	2
57	Histone deacetylase inhibitors: a patent review (2009 â€“ 2011). Expert Opinion on Therapeutic Patents, 2013, 23, 1-17.	5.0	37
58	Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring. European Journal of Medicinal Chemistry, 2013, 66, 56-68.	5.5	16
59	Genista sessilifolia DC . extracts induce apoptosis across a range of cancer cell lines. Cell Proliferation, 2013, 46, 183-192.	5.3	22
60	HDAC Inhibitors Repress BARD1 Isoform Expression in Acute Myeloid Leukemia Cells via Activation of miR-19a and/or b. PLoS ONE, 2013, 8, e83018.	2.5	40
61	Trials with â€˜epigeneticâ€™ drugs: An update. Molecular Oncology, 2012, 6, 657-682.	4.6	208
62	UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression. Oncogene, 2012, 31, 5061-5072.	5.9	77
63	Developing novel non-hydroxamate histone deacetylaseinhibitors: the chelidamic warhead. MedChemComm, 2012, 3, 298-304.	3.4	7
64	Indole-Derived Psammaplin A Analogues as Epigenetic Modulators with Multiple Inhibitory Activities. Journal of Medicinal Chemistry, 2012, 55, 9467-9491.	6.4	48
65	Rarity of Human T Helper 17 Cells Is due to Retinoic Acid Orphan Receptor-Dependent Mechanisms that Limit Their Expansion. Immunity, 2012, 36, 201-214.	14.3	103
66	The new lowâ€toxic histone deacetylase inhibitor Sâ€(2) induces apoptosis in various acute myeloid leukaemia cells. Journal of Cellular and Molecular Medicine, 2012, 16, 1758-1765.	3.6	14
67	Discovery of Salermide-Related Sirtuin Inhibitors: Binding Mode Studies and Antiproliferative Effects in Cancer Cells Including Cancer Stem Cells. Journal of Medicinal Chemistry, 2012, 55, 10937-10947.	6.4	84
68	Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. Leukemia, 2012, 26, 662-674.	7.2	72
69	Sirtuins and Disease: The Road Ahead. Frontiers in Pharmacology, 2012, 3, 4.	3.5	157
70	Nonlinear protein - nucleic acid crosslinking induced by femtosecond UV laser pulses in living cells. Laser Physics Letters, 2012, 9, 234-239.	1.4	21
71	Design, Synthesis, and Biological Evaluation of 2â€Aminobenzanilide Derivatives as Potent and Selective HDAC Inhibitors. ChemMedChem, 2012, 7, 1256-1266.	3.2	16
72	Psidium guajava L. antiâ€neoplastic effects: induction of apoptosis and cell differentiation. Cell Proliferation, 2012, 45, 22-31.	5.3	45

#	Article	IF	Citations
73	Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions. Recent Patents on Anti-Cancer Drug Discovery, 2011, 6, 131-145.	1.6	28
74	Novel Cinnamyl Hydroxyamides and 2â€Aminoanilides as Histone Deacetylase Inhibitors: Apoptotic Induction and Cytodifferentiation Activity. ChemMedChem, 2011, 6, 698-712.	3.2	17
75	Epigenetic profiling of the antitumor natural product psammaplin A and its analogues. Bioorganic and Medicinal Chemistry, 2011, 19, 3637-3649.	3.0	52
76	Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: Coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile. Bioorganic and Medicinal Chemistry, 2011, 19, 3659-3668.	3.0	30
77	Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008. Molecular Cancer Therapeutics, 2011, 10, 2394-2404.	4.1	49
78	N ^{Îµ} -lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2795-2800.	7.1	93
79	Histone deacetylase inhibitors: clinical implications for hematological malignancies. Clinical Epigenetics, 2010, 1, 25-44.	4.1	20
80	PML-RARÎ±/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell, 2010, 17, 173-185.	16.8	276
81	Identification of Triâ€and Tetracyclic Pyrimidinediones as Sirtuin Inhibitors. ChemMedChem, 2010, 5, 674-677.	3.2	40
82	Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene, 2010, 29, 105-116.	5.9	73
83	Epigenetic Silencing of Peroxisome Proliferator-Activated Receptor Î³ Is a Biomarker for Colorectal Cancer Progression and Adverse Patients' Outcome. PLoS ONE, 2010, 5, e14229.	2.5	69
84	HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. Journal of Molecular Endocrinology, 2010, 45, 219-228.	2.5	53
85	Growth Factor-Antagonized Rexinoid Apoptosis Involves Permissive PPARÎ³/RXR Heterodimers toÂActivate the Intrinsic Death Pathway by NO. Cancer Cell, 2009, 16, 220-231.	16.8	31
86	Pyrroleâ€Based Hydroxamates and 2â€Aminoanilides: Histone Deacetylase Inhibition and Cellular Activities. ChemMedChem, 2009, 4, 1411-1415.	3.2	9
87	Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDACâ€“MEF2 complexes. EMBO Reports, 2009, 10, 776-782.	4.5	125
88	Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene, 2009, 28, 781-791.	5.9	244
89	Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1132-1135.	2.2	63
90	Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6284-6288.	2.2	12

#	Article	IF	Citations
91	TNF-related apoptosis-inducing ligand: Signalling of a â€˜smartâ€™ molecule. International Journal of Biochemistry and Cell Biology, 2009, 41, 460-466.	2.8	23
92	New pyrrole-based histone deacetylase inhibitors: Binding mode, enzyme- and cell-based investigations. International Journal of Biochemistry and Cell Biology, 2009, 41, 235-247.	2.8	24
93	Study of 1,4-Dihydropyridine Structural Scaffold: Discovery of Novel Sirtuin Activators and Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 5496-5504.	6.4	147
94	Molecular analysis of the apoptotic effects of BPA in acute myeloid leukemia cells. Journal of Translational Medicine, 2009, 7, 48.	4.4	27
95	Synthesis of Benzamides Related to Anacardic Acid and Their Histone Acetyltransferase (HAT) Inhibitory Activities. ChemMedChem, 2008, 3, 1435-1442.	3.2	52
96	Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents. Bioorganic and Medicinal Chemistry, 2008, 16, 7992-8002.	3.0	11
97	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: Histone deacetylase inhibition and in-cell activities. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2530-2535.	2.2	22
98	Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2788-2792.	2.2	96
99	HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 2030-2038.	4.1	48
100	Effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability. Journal of Translational Medicine, 2008, 6, 27.	4.4	18
101	Epigenetic Multiple Ligands: Mixed Histone/Protein Methyltransferase, Acetyltransferase, and Class III Deacetylase (Sirtuin) Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 2279-2290.	6.4	133
102	Histone deacetylase inhibitors and hemoglobin F induction in Î²-thalassemia. International Journal of Biochemistry and Cell Biology, 2008, 40, 2341-2347.	2.8	14
103	Identification of Two New Synthetic Histone Deacetylase Inhibitors That Modulate Globin Gene Expression in Erythroid Cells from Healthy Donors and Patients with Thalassemia. Molecular Pharmacology, 2007, 72, 1111-1123.	2.3	30
104	Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity. International Journal of Biochemistry and Cell Biology, 2007, 39, 1510-1522.	2.8	13
105	Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities. International Journal of Biochemistry and Cell Biology, 2007, 39, 1902-1914.	2.8	89
106	Bispyridinium Dienes:Â Histone Deacetylase Inhibitors with Selective Activities. Journal of Medicinal Chemistry, 2007, 50, 2497-2505.	6.4	48
107	Synthesis and Biological Validation of Novel Synthetic Histone/Protein Methyltransferase Inhibitors. ChemMedChem, 2007, 2, 987-991.	3.2	52
108	Small-Molecule Inhibitors of Histone Acetyltransferase Activity:Â Identification and Biological Properties. Journal of Medicinal Chemistry, 2006, 49, 6897-6907.	6.4	134

#	Article	IF	Citations
109	Synthesis and Biological Properties of Novel, Uracil-Containing Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 6046-6056.	6.4	57
110	Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. Journal of Cellular Biochemistry, 2006, 98, 1163-1184.	2.6	43
111	Piroxicam and Cisplatin in a Mouse Model of Peritoneal Mesothelioma. Clinical Cancer Research, 2006, 12, 6133-6143.	7.0	39
112	Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Medicine, 2005, 11, 77-84.	30.7	567
113	Rexinoid-Triggered Differentiation and Tumor-Selective Apoptosis of Acute Myeloid Leukemia by Protein Kinase Aâ€“Mediated Desubordination of Retinoid X Receptor. Cancer Research, 2005, 65, 8754-8765.	0.9	111
114	TRAIL: At the Center of Drugable Anti-Tumor Pathways. Cell Cycle, 2005, 4, 914-918.	2.6	13
115	Acute myeloid leukemia: Therapeutic impact of epigenetic drugs. International Journal of Biochemistry and Cell Biology, 2005, 37, 1752-1762.	2.8	47
116	Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides. Journal of Medicinal Chemistry, 2005, 48, 3344-3353.	6.4	193